Antares Pharma (NASDAQ:ATRS) Upgraded to “Hold” by BidaskClub

BidaskClub upgraded shares of Antares Pharma (NASDAQ:ATRS) from a sell rating to a hold rating in a research report sent to investors on Saturday, October 19th, BidAskClub reports.

ATRS traded down $0.04 during trading on Friday, hitting $3.64. The company’s stock had a trading volume of 3,598,100 shares, compared to its average volume of 1,010,182. Antares Pharma has a 12 month low of $2.53 and a 12 month high of $3.96. The firm’s 50 day moving average price is $3.45 and its two-hundred day moving average price is $3.18. The company has a quick ratio of 2.87, a current ratio of 3.46 and a debt-to-equity ratio of 1.01. The stock has a market capitalization of $602.51 million, a price-to-earnings ratio of -91.00 and a beta of 0.80.

Antares Pharma (NASDAQ:ATRS) last posted its earnings results on Tuesday, November 5th. The specialty pharmaceutical company reported $0.01 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.03. Antares Pharma had a negative net margin of 0.56% and a negative return on equity of 1.43%. The firm had revenue of $34.31 million for the quarter, compared to analyst estimates of $26.36 million. On average, sell-side analysts forecast that Antares Pharma will post -0.08 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of ATRS. Cortina Asset Management LLC grew its holdings in Antares Pharma by 100.3% during the 2nd quarter. Cortina Asset Management LLC now owns 2,072,605 shares of the specialty pharmaceutical company’s stock worth $6,819,000 after acquiring an additional 1,037,675 shares during the last quarter. BlackRock Inc. grew its position in Antares Pharma by 10.0% during the second quarter. BlackRock Inc. now owns 10,904,306 shares of the specialty pharmaceutical company’s stock valued at $35,875,000 after buying an additional 993,787 shares during the period. River & Mercantile Asset Management LLP bought a new position in Antares Pharma during the second quarter valued at about $2,603,000. State of New Jersey Common Pension Fund D bought a new position in Antares Pharma during the third quarter valued at about $2,549,000. Finally, Nuveen Asset Management LLC bought a new position in Antares Pharma during the second quarter valued at about $2,252,000. 38.74% of the stock is currently owned by hedge funds and other institutional investors.

About Antares Pharma

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Recommended Story: Producer Price Index (PPI)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with's FREE daily email newsletter.